(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
9 September 2011 (09.09.2011)

PCT

(10) International Publication Number
WO 2011/109471 A1

(51) International Patent Classification:
C07D 487/04 (2006.01) *A61P 31/12* (2006.01)
A61K 31/407 (2006.01) *A61P 37/00* (2006.01)

(21) International Application Number:
PCT/US2011/026806

(22) International Filing Date:
2 March 2011 (02.03.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/339,362 3 March 2010 (03.03.2010) US

(71) Applicant *(for all designated States except US)*: **ARENA PHARMACEUTICALS, INC.** [US/US]; 6166 Nancy Ridge Drive, San Diego, California 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **JONES, Robert M.** [GB/US]; 10937 Corte luz del Sol, San Diego, California 92130 (US). **BUZARD, Daniel J.** [US/US]; 14494 Janal Way, San Diego, California 92129 (US). **GHARBAOUI, Tawfik** [MA/US]; 2340 Lomica Place, Escondido, California 92029 (US). **JOHNSON, Benjamin R.** [GB/US]; 8574 Summerdale Road, No. 146, San Diego, California 92126 (US). **KASEM, Michelle** [US/US]; 1112 Paseo Entrada, Chula Vista, California 91910 (US). **SCHRADER, Thomas O.** [US/US]; 575 6th Avenue, No. 508, San Diego, California 92101 (US). **STIRN, Scott** [US/US]; 14710 Carmel Ridge Road, San Diego, California 92128 (US).

(74) Agents: **SPRUCE, Lyle W.** et al.; Arena Pharmaceuticals, Inc., 6166 Nancy Ridge Drive, San Diego, California 92121 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) **Title**: PROCESSES FOR THE PREPARATION OF S1P1 RECEPTOR MODULATORS AND CRYSTALLINE FORMS THEREOF



(Ia)

(57) **Abstract**: The present invention relates to salts, processes, and process intermediates useful in the preparation of (R)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid of Formula (Ia), salts, and crystalline forms thereof. The compound (R)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid has been identified as an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).

WO 2011/109471 A1